{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:28:59Z","timestamp":1790908139915,"version":"4.1.0"},"reference-count":40,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T00:00:00Z","timestamp":1145923200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Schering-Plough Nordic Biotech"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2006,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Conventional interferon\u2010\u03b1 (IFN) is an effective treatment for patients with myeloproliferative disorders. However, many patients discontinue therapy because of side effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>In this 24\u2010month, Phase II feasibility study of pegylated interferon \u03b1\u20102b (PEG\u2010IFN) treatment, a starting dose of 0.5 \u03bcg\/kg per week was received by 21 patients with polycythemia vera (PV) and 21 patients with essential thrombocythemia (ET). The treatment objective, a complete platelet response (CR), was a platelet count &lt;400 \u00d7 10<jats:sup>9<\/jats:sup>\/L in symptomatic patients and &lt;600 in asymptomatic patients. Neutrophil polycythemia rubra vera\u20101 (PRV\u20101) messenger RNA expression was analyzed prior to and during therapy. Quality of life (QoL) was investigated by using the European Organization for Research and Treatment of Cancer QLQ\u2010C30 questionnaire.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>At 6 months, 29 of 42 patients (69%) had achieved a CR after a median of 83 days. The CR rate was not related to diagnosis, gender, or previous therapy. Nineteen patients completed the planned 2\u2010year treatment in CR. No thromboembolic or bleeding complications were observed. Phlebotomy requirements were reduced in the majority of patients with PV. Five of 14 patients (36%) who initially were positive for PRV\u20101 achieved normalized PRV\u20101 expression under PEG\u2010IFN treatment. Side effects were the cause of therapy failure in 16 of 23 patients. However, only 8 of 19 patients reported any side effects at 2 years. The QLQ\u2010C30 revealed clinically significant impairments in several aspects of QoL at 6 months; however, at 2 years, QoL measurements were not different from baseline.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>PEG\u2010IFN effectively reduced platelet counts in 29 of 42 patients, but only 19 patients maintained a CR at 2 years. The reversal of PRV\u20101 positivity noted in a subset of patients suggested that PEG\u2010IFN may have an effect on the malignant clone. PEG\u2010IFN is a valuable therapeutic alternative for patients who tolerate its initial side effects. Cancer 2006. \u00a9 2006 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.21900","type":"journal-article","created":{"date-parts":[[2006,4,25]],"date-time":"2006-04-25T16:57:25Z","timestamp":1145984245000},"page":"2397-2405","source":"Crossref","is-referenced-by-count":105,"title":["A phase II trial of pegylated interferon \u03b1\u20102b therapy for polycythemia vera and essential thrombocythemia"],"prefix":"10.1002","volume":"106","author":[{"given":"Jan","family":"Samuelsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Hasselbalch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oystein","family":"Bruserud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snezana","family":"Temerinac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Brandberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Merup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olle","family":"Linder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Bjorkholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike L.","family":"Pahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Birgegard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Nordic Study Group for Myeloproliferative Disorders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,5,18]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-9-199511010-00003"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.062"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1987.tb02349.x"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(78)92098-6"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043800"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3426"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.7.2319"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00199157"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92142-9"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(89)90384-7"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V76.4.664.664","article-title":"A new treatment for polycythemia vera: recombinant interferon alfa","volume":"76","author":"Silver RT","year":"1990","journal-title":"Blood."},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01697629"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1994.tb04752.x"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050563"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609074371"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V98.6.1708"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418600750013384"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1983.tb09716.x"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S0022-3999(96)00216-4","article-title":"International experience with the Hospital Anxiety and Depression Scale\u2014a review of validation data and clinical results","volume":"42","author":"Herrman C","year":"1997","journal-title":"J Psychosom Res."},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-03-0919"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.1.139"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/028418602317314064"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-002-0533-4"},{"key":"e_1_2_5_30_2","doi-asserted-by":"crossref","first-page":"424a","DOI":"10.1182\/blood.V104.11.1517.1517","article-title":"Peg\u2010intron for myeloproliferative diseases: an update of ongoing Phase II study","volume":"104","author":"Verstovsek S","year":"2004","journal-title":"Blood."},{"key":"e_1_2_5_31_2","first-page":"919a","article-title":"Peg Intron in essential thrombocythemia. Two years of treatment in 90 patients","volume":"102","author":"Gugliotta L","year":"2003","journal-title":"Blood."},{"issue":"2","key":"e_1_2_5_32_2","first-page":"264a","article-title":"PVSG and WHO bone marrow evaluation in 90 essential thrombocythemia patients treated with PEG interferon \u03b1\u20102\u2010b. Preliminary results","volume":"90","author":"Gugliotta L","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_5_33_2","first-page":"1333","article-title":"Pegylated interferon for the treatment of high risk essential thrombocythemia: results of a Phase II study","volume":"90","author":"Langer C","year":"2005","journal-title":"Haematologica."},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90017-6"},{"key":"e_1_2_5_35_2","first-page":"520","article-title":"Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders","volume":"89","author":"Birgegard G","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2004.10.002"},{"key":"e_1_2_5_37_2","first-page":"1306","article-title":"A long\u2010term study of young patients with essential thrombocythemia treated with anagrelide","volume":"89","author":"Mazzucconi MG","year":"2004","journal-title":"Haematologica."},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2257.2004.00637.x"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-2287"},{"key":"e_1_2_5_40_2","first-page":"349","article-title":"Quantitative real\u2010time polymerase chain reaction shows that treatment with interferon reduces the initially upregulated PRV\u20101 expression in polycythemia vera patients","volume":"88","author":"Fruehauf S","year":"2003","journal-title":"Haematologica."},{"key":"e_1_2_5_41_2","first-page":"1272","article-title":"The effects of hydroxyurea on PRV\u20101 expression in patients with essential thrombocythemia and polycythemia vera","volume":"89","author":"Johansson P","year":"2004","journal-title":"Haematologica."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.21900","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.21900","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:11:28Z","timestamp":1760292688000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.21900"}},"subtitle":["Feasibility, clinical and biologic effects, and impact on quality of life"],"short-title":[],"issued":{"date-parts":[[2006,5,18]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2006,6]]}},"alternative-id":["10.1002\/cncr.21900"],"URL":"https:\/\/doi.org\/10.1002\/cncr.21900","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,5,18]]}}}